Nebenwirkungen · Flixabi
Flixabi 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 21
HOS-222790 · Präparat HOS-217086
Infections In the REACH study, infections were reported in 56.3% of randomised subjects treated with infliximab. Infections were reported more frequently for subjects who received q8 week as opposed to q12 week infusions (73.6% and 38.0%, respectively), while serious infections were reported for 3 subjects in the q8 week and 4 subjects in the q12 week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Three cases of pneumonia (1 serious) and 2 cases of herpes zoster (both non-serious) were reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T12:15:00Z · SHA-256 01df900501649a0c225dc84d8f07b05b21b1d4deab3ad6c2da84a4b6879f8b57 · Passage 08886d8dee17656cfed05550e55f954809beb2b0e258418944de10fb486878df · Zeichen 28103–28741 im Abschnitt